BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 29602320)

  • 1. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.
    Lee KM; Jung D; Hwang H; Son KL; Kim TY; Im SA; Lee KH; Hahm BJ
    J Psychosom Res; 2018 May; 108():14-19. PubMed ID: 29602320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study.
    Pereira S; Fontes F; Sonin T; Dias T; Fragoso M; Castro-Lopes JM; Lunet N
    Support Care Cancer; 2016 Apr; 24(4):1571-81. PubMed ID: 26384827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer.
    Son KL; Jung D; Lee KM; Yeom CW; Oh GH; Kim TY; Im SA; Lee KH; Spiegel D; Hahm BJ
    J Korean Med Sci; 2022 Feb; 37(5):e34. PubMed ID: 35132840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing gait, balance, and muscle strength among breast cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): study protocol for a randomized controlled clinical trial.
    Teran-Wodzinski P; Haladay D; Vu T; Ji M; Coury J; Adams A; Schwab L; Visovsky C
    Trials; 2022 Apr; 23(1):363. PubMed ID: 35477489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
    Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
    Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
    Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
    Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
    Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
    Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
    Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
    Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.
    Kleckner IR; Jusko TA; Culakova E; Chung K; Kleckner AS; Asare M; Inglis JE; Loh KP; Peppone LJ; Miller J; Melnik M; Kasbari S; Ossip D; Mustian KM
    Breast Cancer Res Treat; 2021 Sep; 189(2):521-532. PubMed ID: 34191201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
    Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
    Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.
    Sreeram K; Seaton R; Greenwald MK; Kamgar M; Assad H; Baird T; Schwartz AG; Ruterbusch J; Simon MS
    Cancer Causes Control; 2023 May; 34(5):459-468. PubMed ID: 36934365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer.
    Verhoeff-Jahja R; Ter Kuile MM; Weijl NI; Oosterkamp R; Cloos M; Portielje JEA; Kroep JR; Hinnen C
    Support Care Cancer; 2022 Aug; 30(8):6947-6953. PubMed ID: 35543818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
    Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
    Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
    Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
    Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
    Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
    Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Kuriyama A; Endo K
    Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.